Effects of risedronate and alfacalcidol on parameters of atherosclerosis in type 2 diabetes patients with osteoporosis
Not Applicable
- Conditions
- Type 2 diabetes with osteoporosis
- Registration Number
- JPRN-UMIN000001992
- Lead Sponsor
- Department of Internal Medicine 1, Shimane University School of Medicine
- Brief Summary
After 1 year treatment with risedronate and alfacalcidol, plaque score and abdominal aortic calcification score in the osteoporosis group were not statistically changed, while both two parameters in the control group were significantly increased
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Nobody had hepatic or renal dysfunction or nutritional derangements. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plaque score and abdominal aortic calcification score
- Secondary Outcome Measures
Name Time Method